Baycol, also known as Cerivastatin Sodium, was approved for use in 1997. It is a popular cholesterol-lowering drug and is prescribed to control the excess cholesterol in the bloodstream that leads to hardening of the arteries and heart disease. Approximately 700,000 Americans were prescribed with the drug. Baycol was intended to lower both total cholesterol and LDL ("bad") cholesterol, while raising the HDL ("good") cholesterol that clears the arteries. Patients taking Baycol, however, have experienced severe rhabdomyolysis resulting in kidney failure and death. On August 8, 2001, Bayer, the manufacturer of Baycol, voluntarily withdrew the drug from the market due to reports of fatal rhabdomyolysis.
The FDA has received 31 reports of deaths due to severe Rhabdomyolysis associated with Baycol. Bayer, however, is attributing 52 deaths to Baycol. To date, many lawsuits have already been filed and several are seeking class action status.
- Baycol Lawsuits; New Baycol Cases - Jul 01 2004
- Minnesota Court Orders Supplemental Discovery in Baycol Litigation - Apr 01 2004
- Baycol Settlements on the Rise - May 08 2003
- Bayer Victorious in First Baycol Trial - Mar 18 2003
- First Baycol Trial Begins in Texas - Feb 18 2003
- Bayer CEO Ready to Settle Baycol Lawsuits in Individual Cases - Aug 12 2002
- Law Firm Announces Class Action Lawsuit Against Bayer - Sep 06 2001
- Bayer Facing Mounting US Lawsuits over Anti-Cholesterol Drug - Aug 17 2001
- Bayer Corporation Voluntarily Recalls Baycol - Aug 08 2001
- Letter (Bayer Corporation): Prescribing Information Changes to Reduce Risk of Myopathy (Weakening of the Muscles) and Rhadomyolysis - May 21 2001